started · updated
India caps trade margins on cancer drugs at 30%
The Indian government has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines to improve affordability. This measure targets high-priced drugs, including some patented medicines, to curb excessive mark-ups in the supply chain. An analysis by the National Pharmaceutical Pricing Authority (NPPA) revealed that non-scheduled anti-cancer drugs previously carried average mark-ups of 170%, with some exceeding 700%.
The price reduction is expected to be significant, with retail prices potentially dropping by 20% to 70%. This move is projected to save cancer patients approximately Rs 2,500 crore annually. The regulation will apply to branded, generic, domestically produced, and imported medicines. To ensure supply stability, manufacturers have been instructed to maintain current production levels.
A committee under the Directorate General of Health Services (DGHS) is currently finalizing the specific list of medicines that will fall under this new regime. The decision follows concerns raised by the Supreme Court and various state health departments, including Karnataka, regarding the high cost of life-saving treatments. While the cap may impact hospital margins in the short term, analysts suggest hospitals may manage the impact through cost rationalization and gradual adjustments to procedure prices.
Entities
Department of Pharmaceuticals · Director General of Health Services · Directorate General of Health Services · Government of India · India · Jefferies · Karnataka Health Department · Ministry of Chemicals and Fertilizers · National Pharmaceutical Pricing Authority
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 8 SOURCES] The government approved a 30% trade margin cap on non-scheduled anti-cancer medicines relative to their MRP. thefederal.com · hindi.asianetnews.com · www.latestly.com · www.news18.com · www.indiatv.in · +2 more
- [○ 1 SOURCE] Hospitals may mitigate the impact of the price cap through cost rationalization and gradual increases in procedure prices.
- [○ 1 SOURCE] The new price regulation is expected to take effect within 10 days. www.latestly.com
- [● 6 SOURCES] A committee under the DGHS will finalize the list of medicines to be covered by the new margin cap. thefederal.com · hindi.asianetnews.com · www.latestly.com · www.tv9hindi.com · www.news18.com
- [● 8 SOURCES] Medicine prices could drop by up to 70%, resulting in annual savings of approximately Rs 2,500 crore for patients. thefederal.com · hindi.asianetnews.com · www.latestly.com · www.news18.com · www.indiatv.in · +1 more
- [● 4 SOURCES] Non-scheduled anti-cancer medicines have an average price mark-up of 170%, with some cases exceeding 700%. thefederal.com · hindi.asianetnews.com · www.tv9hindi.com